Abstract
Hyperhomocysteinaemia almost invariably occurs in patients with end-stage renal disease (ESRD), but there is debate whether, within the group of ESRD patients, higher or lower plasma homocysteine concentrations are related to an increased risk of vascular disease. Homocysteine is thought to be vasculotoxic in high concentrations, but it may also lead to elevated levels of its precursor, S-adenosylhomocysteine (AdoHcy), which is a potent inhibitor of the transmethylation pathway, in which S-adenosylmethionine (AdoMet) donates its methyl group to a variety of acceptors. Impairment of this transmethylation pathway in ESRD patients has been suggested by high AdoHcy levels, decreased AdoMet/AdoHcy ratios, decreased protein repair requiring methyltransferases, and by DNA hypomethylation. Stable isotope techniques using labelled methionine have indeed demonstrated a decreased whole body transmethylation flux in ESRD patients. These studies have also shown that folic acid treatment is capable of restoring transmethylation rates to normal values. The remaining hyperhomocysteinaemia after folic acid treatment in ESRD is probably due to a persistent impairment of homocysteine clearance through transsulphuration. DNA hypomethylation with its concurrent alterations in gene expression is largely improved by folate treatment. The adverse effects of hyperhomocysteinaemia in ESRD may thus be related to impaired transmethylation. Normalisation of plasma homocysteine does not seem to be required to restore transmethylation to normal levels in ESRD patients.
References
1. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002;288:2015–22.10.1001/jama.288.16.2015Search in Google Scholar PubMed
2. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61:609–14.10.1046/j.1523-1755.2002.00144.xSearch in Google Scholar PubMed
3. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57:1727–35.10.1046/j.1523-1755.2000.00018.xSearch in Google Scholar PubMed
4. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15:442–53.10.1097/01.ASN.0000107564.60018.51Search in Google Scholar PubMed
5. van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int 2001; 59(Suppl 78):S234–7.10.1046/j.1523-1755.2001.07859.xSearch in Google Scholar
6. van Guldener C, Stehouwer CD. Homocysteine metabolism in renal disease. Clin Chem Lab Med 2003; 41:1412–7.10.1515/CCLM.2003.217Search in Google Scholar PubMed
7. Laukkanen MO, Mannermaa S, Hiltunen MO, Aittomaki S, Airenne K, Janne J, et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol 1999; 19:2171–8.10.1161/01.ATV.19.9.2171Search in Google Scholar PubMed
8. Hiltunen MO, Turunen MP, Hakkinen TP, Rutanen J, Hedman M, Makinen K, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med 2002; 7:5–11.10.1191/1358863x02vm418oaSearch in Google Scholar PubMed
9. Wang H, Yoshizumi M, Lai K, Tsai JC, Perrella MA, Haber E, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272:25380–5.10.1074/jbc.272.40.25380Search in Google Scholar PubMed
10. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001; 10:433–43.10.1093/hmg/10.5.433Search in Google Scholar PubMed
11. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002; 99:5606–11.10.1073/pnas.062066299Search in Google Scholar PubMed PubMed Central
12. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000; 275:29318–23.10.1074/jbc.M002725200Search in Google Scholar PubMed
13. Castro R, Rivera I, Struys EA, Jansen EE, Ravasco P, Camilo ME, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003; 49:1292–6.10.1373/49.8.1292Search in Google Scholar PubMed
14. Loehrer FM, Angst CP, Brunner FP, Haefeli WE, Fowler B. Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998; 13:656–61.10.1093/ndt/13.3.656Search in Google Scholar PubMed
15. Stam F, van Guldener C, ter Wee PM, Kulik W, Smith DE, Jakobs C, et al. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine. Am J Physiol Renal Physiol 2004; 287:F215–23.10.1152/ajprenal.00376.2003Search in Google Scholar PubMed
16. Perna AF, Ingrosso D, Zappia V, Galletti P, Capasso G, De Santo NG. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest 1993; 91:2497–503.Search in Google Scholar
17. Poirier LA, Brown AT, Fink LM, Wise CK, Randolph CJ, Delongchamp RR, et al. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy. Metabolism 2001; 50:1014–8.10.1053/meta.2001.25655Search in Google Scholar PubMed
18. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995; 47:247–53.10.1038/ki.1995.31Search in Google Scholar PubMed
19. Perna AF, D'Aniello A, Lowenson JD, Clarke S, De Santo NG, Ingrosso D. D-aspartate content of erythrocyte membrane proteins is decreased in uremia: implications for the repair of damaged proteins. J Am Soc Nephrol 1997; 8:95–104.10.1681/ASN.V8195Search in Google Scholar PubMed
20. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 1997; 8:1899–907.10.1681/ASN.V8121899Search in Google Scholar PubMed
21. Perna AF, Castaldo P, De Santo NG, di Carlo E, Cimmino A, Galletti P, Zappia V, Ingrosso D. Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: implications for mechanism. Kidney Int 2001; 59:2299–308.10.1046/j.1523-1755.2001.00747.xSearch in Google Scholar PubMed
22. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, de Bonis ML, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003; 361:1693–99.10.1016/S0140-6736(03)13372-7Search in Google Scholar
23. van Guldener C, Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999; 56:1064–71.10.1046/j.1523-1755.1999.00624.xSearch in Google Scholar
24. Storch KJ, Wagner DA, Burke JF, Young VR. [1-13C; methyl-2H3]methionine kinetics in humans: methionine conservation and cystine sparing. Am J Physiol Endocrinol Metab 1990; 258:E790–8.10.1152/ajpendo.1990.258.5.E790Search in Google Scholar
25. Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hultberg B. The effect of excess methionine intake on plasma homocysteine after a methionine loading test in humans. Clin Chim Acta 1990; 192:69–76.10.1016/0009-8981(90)90273-USearch in Google Scholar
26. Ward M, McNulty H, Pentieva K, McPartlin J, Strain JJ, Weir DG, et al. Fluctuations in dietary intake do not alter plasma homocysteine concentration in healthy men. J Nutr 2000; 130:2653–7.10.1093/jn/130.11.2653Search in Google Scholar PubMed
27. Noga AA, Stead LM, Zhao Y, Brosnan ME, Brosnan JT, Vance DE. Plasma homocysteine is regulated by phospholipid methylation. J Biol Chem 2003; 278:5952–5.10.1074/jbc.M212194200Search in Google Scholar PubMed
28. Brulez HF, van Guldener C, Donker AJ, ter Wee PM. The impact of an amino-acids based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 1999; 14:154–9.10.1093/ndt/14.1.154Search in Google Scholar PubMed
29. Taes YE, Delanghe JR, de Vriese AS, Rombaut R, van Camp J, Lameire NH. Creatine supplementation decreases homocysteine in an animal model of uremia. Kidney Int 2001; 64:1331–7.10.1046/j.1523-1755.2003.00206.xSearch in Google Scholar PubMed
30. Taes YE, Delanghe JR, de Bacquer D, Langlois M, Stevens L, Geerolf I, et al. Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients. Kidney Int 2004; 66:2422–8.10.1111/j.1523-1755.2004.66019.xSearch in Google Scholar PubMed
31. Stam F, van Guldener C, ter Wee PM, Jakobs C, de Meer K, Stehouwer CD. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int 2005; 67:259–64.10.1111/j.1523-1755.2005.00076.xSearch in Google Scholar PubMed
32. Perna AF, Ingrosso D, Satta E, Lombardi C, Galletti P, D'Aniello A, et al. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. J Am Soc Nephrol 2004; 15:2747–54.10.1097/01.ASN.0000141041.71717.11Search in Google Scholar PubMed
©2005 by Walter de Gruyter Berlin New York
